Next Article in Journal
Premature Ovarian Insufficiency: Procreative Management and Preventive Strategies
Next Article in Special Issue
Clinical Activity and Tolerability of SL-401 (Tagraxofusp): Recombinant Diphtheria Toxin and Interleukin-3 in Hematologic Malignancies
Previous Article in Journal
Constrained α-Helical Peptides as Inhibitors of Protein-Protein and Protein-DNA Interactions
Article Menu
Issue 1 (March) cover image

Export Article

Open AccessReview

Immunotoxins Targeting B cell Malignancy—Progress and Problems With Immunogenicity

1
Laboratory of Molecular Cancer Therapeutics, Masonic Cancer Center, Department of Therapeutic Radiology-Radiation Oncology, University of Minnesota, Minneapolis, MN 55455, USA
2
National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
*
Author to whom correspondence should be addressed.
Biomedicines 2019, 7(1), 1; https://doi.org/10.3390/biomedicines7010001
Received: 28 November 2018 / Revised: 17 December 2018 / Accepted: 19 December 2018 / Published: 21 December 2018
(This article belongs to the Special Issue Immunotoxins: Future Advances and Directions)
  |  
PDF [1502 KB, uploaded 21 December 2018]
  |  

Abstract

Few immunotoxins or targeted toxins have become mainline cancer therapies. Still immunotoxins continue to be of major interest and subject of research and development as alternative therapies for drug resistant cancer. A major matter of concern continues to be immunogenicity exemplified by the anti-toxin response of the treated patient. Since some of our most effective toxins are bacterial in nature and bacterial proteins are highly immunogenic, this review describes some efforts to address this pressing issue. View Full-Text
Keywords: diphtheria toxin; pseudomonas exotoxin; immunogenicity; B-cell malignancies; CD19; CD22; deimmunized; immunotoxin; chemo-immunosuppression diphtheria toxin; pseudomonas exotoxin; immunogenicity; B-cell malignancies; CD19; CD22; deimmunized; immunotoxin; chemo-immunosuppression
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Vallera, D.A.; Kreitman, R.J. Immunotoxins Targeting B cell Malignancy—Progress and Problems With Immunogenicity. Biomedicines 2019, 7, 1.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top